Table 1.
Patient characteristics
| Index | Total (N = 218) | With complications (n = 115) | Without complications (n = 103) | P-value |
|---|---|---|---|---|
| Age (years) | 56.2 ± 9.2 | 55.9 ± 9.8 | 56.5 ± 8.5 | 0.633 |
| Male | 182 (83.5%) | 96 (83.5%) | 86 (83.5%) | 0.997 |
| BMI (kg/m2) | 24.2 ± 3.5 | 23.9 ± 3.7 | 24.5 ± 3.1 | 0.168 |
| Hypertension | 36 (16.5%) | 21 (18.3%) | 15 (14.6%) | 0.463 |
| Diabetes | 53 (24.3%) | 32 (27.8%) | 21 (20.4%) | 0.201 |
| ALT | 23.9 (6.0–318.0) | 26.0 (6.0–255.0) | 22.0 (9.0–318.0) | 0.096 |
| AST | 28.0 (11.1–414.0) | 31.0 (11.1–362.0) | 25.0 (12.0–414.0) | 0.011 |
| GGT | 33.0 (9.0–469.0) | 41.0 (9.0–469.0) | 28.0 (12.0–465.0) | 0.003 |
| TP | 64.5 (31.0–85.0) | 64.2 (51.0–85.0) | 65.0 (31.0–76.8) | 0.555 |
| ALB | 37.7 (3.5–79.0) | 37.0 (3.5–79.0) | 38.0 (15.0–47.6) | 0.151 |
| TBIL | 16.7 (3.2–191.0) | 17.2 (3.2–191.0) | 16.2 (3.3–64.0) | 0.154 |
| DBIL | 5.4 (0.8–39.7) | 5.8 (1.8–39.7) | 4.6 (0.8–16.7) | 0.079 |
| PT | 12.6 (3.0–18.9) | 12.7 (3.0–18.9) | 12.6 (4.1–18.2) | 0.114 |
| INR | 1.1 (0.9–1.8) | 1.1 (0.9–1.8) | 1.1 (0.9–1.7) | 0.032 |
| HGB | 135.5 (62.0–356.0) | 135.0 (62.0–356.0) | 137.0 (67.0–356.0) | 0.509 |
| PLT | 133.0 (14.8–320.0) | 135.0 (14.8–268.0) | 129.0 (46.0–320.0) | 0.959 |
| LYMPH# | 1.3 (0.1–11.6) | 1.2 (0.1–11.4) | 1.4 (0.3–11.6) | 0.046 |
| LYMPH% | 30.6 (7.7–61.6) | 28.9 (7.7–61.6) | 32.0 (8.1–59.6) | 0.142 |
| NEUT# | 2.4 (0.2–23.1) | 2.3 (0.4–21.2) | 2.5 (0.2–23.1) | 0.571 |
| NEUT% | 56.2 (5.7–88.8) | 56.4 (13.7–85.2) | 55.7 (5.7–88.8) | 0.825 |
| SCr | 74.0 (47.0–324.0) | 72.0 (47.0–195.0) | 75.3 (49.0–324.0) | 0.065 |
| Tumor size (mm) | 17.0 (7.7–50.0) | 19.0 (7.7–50.0) | 16.0 (8.0–41.0) | 0.010 |
| BCLC (0/A) | 108/110 (49.5%/50.5%) | 56/59 (48.7%/51.3%) | 52/51 (50.5%/49.5%) | 0.463 |
| High-risk location | 80 (36.7%) | 42 (36.5%) | 38 (36.9%) | 0.618 |
| CTP grade (A/B) | 154/64 (70.6%/29.4%) | 81/34 (70.4%/29.6%) | 73/30 (70.9%/29.1%) | 0.943 |
| MELD | 6.2 (0.3–16.0) | 6.5 (1.4–16.0) | 6.1 (0.3–14.1) | 0.795 |
| Ablation (MWA/RFA) | 181/37 (83.0%/17.0%) | 99/16 (86.1%/13.9%) | 82/21 (79.6%/20.4%) | 0.303 |
Bold values indicate statistical significance if P < 0.05.
ALB, albumin; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BCLC, Barcelona Clinic Liver Cancer; CTP, Child–Turcotte–Pugh; DBIL, direct bilirubin; GGT, γ-glutamyl transpeptidase; HGB, hemoglobin; INR, international normalized ratio; LYMPH#, lymphocyte absolute value; LYMPH%, lymphocyte percentage; NEUT#, neutrophil absolute value; NEUT%, neutrophil percentage; MELD, Model for End-stage Liver Disease; MWA, microwave ablation; PLT, platelet; PT, prothrombin time; RFA, radiofrequency ablation; SCr, serum creatinine; TBIL, total bilirubin; TP, total protein.